From Yahoo Finance: 2025-04-03 05:47:00

Pfizer’s stock price has dropped significantly in 2025, nearly 60% below its 2022 high, making it unattractive to growth investors due to looming patent expirations. However, value investors may find the stock appealing with a low forward earnings multiple, offering potential upside.

Despite upcoming patent expirations for key drugs, Pfizer’s dividend yield of over 7% remains attractive for income investors. The company has a strong history of dividend growth and ample free cash flow to sustain payouts. Few healthcare stocks offer a higher dividend yield, making Pfizer a solid choice for income-focused investors.

While Pfizer’s growth outlook may not be stellar, its valuation is compelling. Additionally, the company’s dividend yield is unmatched in the healthcare sector. With strong cash flow to support dividends and a long-standing track record, Pfizer remains an enticing option for investors seeking income and value.

The Motley Fool’s Stock Advisor team doesn’t include Pfizer in their top 10 stock picks, emphasizing the potential for significant returns elsewhere. However, Pfizer’s stability and dividend appeal make it an attractive option for investors looking for income and value opportunities.

Read more: Is Pfizer Stock a Buy?